Insider Selling: USANA Health Sciences (NYSE:USNA) Director Sells $34,632.50 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director John Turman Fleming sold 1,750 shares of the stock in a transaction on Friday, October 31st. The shares were sold at an average price of $19.79, for a total transaction of $34,632.50. Following the transaction, the director directly owned 4,565 shares in the company, valued at approximately $90,341.35. The trade was a 27.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

USANA Health Sciences Stock Down 1.2%

USNA stock opened at $20.30 on Thursday. USANA Health Sciences, Inc. has a 52 week low of $18.69 and a 52 week high of $41.83. The firm has a 50-day simple moving average of $26.11 and a 200-day simple moving average of $28.74. The stock has a market capitalization of $370.89 million, a P/E ratio of 23.07, a P/E/G ratio of 0.94 and a beta of 0.61.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Thursday, October 9th. The company reported $0.56 earnings per share (EPS) for the quarter. USANA Health Sciences had a return on equity of 6.96% and a net margin of 1.86%.The company had revenue of $200.22 million for the quarter. USANA Health Sciences has set its Q3 2025 guidance at -0.150–0.150 EPS. On average, analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

USNA has been the subject of several recent research reports. Zacks Research downgraded USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 21st. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of USANA Health Sciences in a report on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Two analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $36.00.

Institutional Trading of USANA Health Sciences

Several large investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. raised its holdings in shares of USANA Health Sciences by 339.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 998 shares of the company’s stock worth $27,000 after acquiring an additional 771 shares during the period. Tower Research Capital LLC TRC increased its position in USANA Health Sciences by 382.5% during the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after purchasing an additional 1,901 shares during the last quarter. CWM LLC increased its position in USANA Health Sciences by 109.7% during the second quarter. CWM LLC now owns 2,762 shares of the company’s stock worth $84,000 after purchasing an additional 1,445 shares during the last quarter. AlphaQuest LLC raised its stake in USANA Health Sciences by 300.9% during the first quarter. AlphaQuest LLC now owns 3,412 shares of the company’s stock worth $92,000 after purchasing an additional 2,561 shares during the period. Finally, Quantbot Technologies LP boosted its holdings in USANA Health Sciences by 19.5% in the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock valued at $121,000 after purchasing an additional 646 shares during the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.